Skip to content

Remimazolam

NERVOUS SYSTEM

Also known as: anerem, aptimyda, byfavo, CNS 7056, CNS 7056B, ONO-2745, ONO-2745BS, remimazolam besylate

OfpEMA approvedFDA approvedPMDA approvedATC N05CD14

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Remimazolam is an ofp drug catalogued in DrugCentral. It was first approved by the PMDA in 2020. DrugCentral lists 5 molecular targets, including GABRA1|GABRA2|GABRA3|GABRA5|GABRG1|GABRG2|GABRG3, Gabrg2|Gabra1|Gabrb2 and Gabrg2|Gabra2|Gabrb2. Recorded indications include Sedation.

  • Approval status: ofp (first approved 2020 by the PMDA).
  • Molecular targets: GABRA1|GABRA2|GABRA3|GABRA5|GABRG1|GABRG2|GABRG3, Gabrg2|Gabra1|Gabrb2, Gabrg2|Gabra2|Gabrb2 and Gabrg2|Gabra3|Gabrb2 (5 listed in DrugCentral).
  • Indications: Sedation.
  • ATC code: N05CD14 (Benzodiazepine derivatives).
  • Molecular formula: C21H19BrN4O2; molecular weight 439.31 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Sedation

Contraindications (1)

  • Non-allergic hypersensitivity to dextran

Mechanism & targets

Molecular targets (5)

TargetGeneActionActivity
GABA-A receptor; benzodiazepine binding siteGABRA1|GABRA2|GABRA3|GABRA5|GABRG1|GABRG2|GABRG3modulatorKi 7.53
GABA-A receptor; alpha-1/beta-2/gamma-2Gabrg2|Gabra1|Gabrb2modulatorEC50 6.44
GABA A receptor alpha-2/beta-2/gamma-2Gabrg2|Gabra2|Gabrb2modulatorEC50 6.18
GABA A receptor alpha-3/beta-2/gamma-2Gabrg2|Gabra3|Gabrb2modulatorEC50 6.04
GABA A receptor alpha-5/beta-2/gamma-2Gabra5|Gabrb2|Gabrg2modulatorEC50 5.86

Regulatory approvals (3)

DateAgencyMarketed asApplicantOrphan
2021-03-26EMA—PAION Netherlands B.V.
2020-07-02FDA—ACACIA
2020-01-23PMDA—Anerem

ATC classification

ATC codeTherapeutic hierarchy
N05CD14NERVOUS SYSTEM › PSYCHOLEPTICS › HYPNOTICS AND SEDATIVES › Benzodiazepine derivatives

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Anaphylactic shock109.8
Vascular access site occlusion105.5

Chemical structure

Molecular formulaC21H19BrN4O2
Molecular weight439.31 g/mol
CAS number308242-62-8
InChIKeyCYHWMBVXXDIZNZ-KRWDZBQOSA-N
PubChem CID9867812
CC1=CN=C2N1C3=C(C=C(C=C3)Br)C(=N[C@H]2CCC(=O)OC)C4=CC=CC=N4

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Remimazolam used for?

DrugCentral lists the following indications for Remimazolam: Sedation.

How does Remimazolam work?

Its molecular targets in DrugCentral include GABRA1|GABRA2|GABRA3|GABRA5|GABRG1|GABRG2|GABRG3 (modulator), Gabrg2|Gabra1|Gabrb2 (modulator), Gabrg2|Gabra2|Gabrb2 (modulator) and Gabrg2|Gabra3|Gabrb2 (modulator).

When was Remimazolam first approved?

Remimazolam was first approved by the PMDA in 2020.

What is the chemical formula of Remimazolam?

Remimazolam has the molecular formula C21H19BrN4O2 and a molecular weight of 439.31 g/mol.

Browse: all drugs starting with R · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval2020-01-23
AgencyPMDA
Targets5
Indications1
FormulaC21H19BrN4O2
DrugCentral ID5400
Interactive profile